the potential of immunotherapies in the myeloma treatment landscape
Published 2 days ago • 63 plays • Length 0:36Download video MP4
Download video MP3
Similar videos
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:02
circulating plasma cell levels as a prognostic biomarker in myeloma
-
4:53
the microbiota as a biomarker for gvhd
-
1:07
identifying operational tolerance pathways after sct & cgvhd immune profiles with machine learning
-
1:05
the prognostic and potentially therapeutic value of liquid biopsy in multiple myeloma
-
1:06:04
itp: novel treatments
-
4:36
haemonetics
-
14:28
cluster of differentiation
-
4:33
impact of covid-19 on hsct and cellular therapies in the us
-
2:30
biomarkers of cardiotoxicity in multiple myeloma
-
4:42
legato demo: hipermab for evaluating the potential of biomarker pilot studies
-
15:51
development of an implantable device for continuous monitoring of blood biomarkers – dr chenyang he
-
2:01
hemocompatibility testing in a flow loop model | protocol preview
-
1:54
fostamatinib and efgartigimod: novel agents in the treatment of itp
-
0:45
difference between quality of life & patient-reported outcomes
-
1:01
challenges with finding biomarkers for immunotherapy
-
24:22
do we have reliable biomarkers to guide use of immunotherapy agents?
-
0:36
versiti diagnostic labs | hematology
-
3:17
are hematologists rational?
-
51:47
artificial intelligence in precision oncology
-
3:38
hematopoietic neoplasm testing at mayo medical laboratories
-
46:33
understanding biomarker testing